Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers

PURPOSE: Pegylated arginine deiminase (ADI-PEG 20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) –negative tumors by converting arginine to citrulline and ammonia. The main aim of this study was to determine the recommended dose, safety, and tolerability of ADI-PEG 20...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Beddowes, Emma, Spicer, James, Chan, Pui Ying, Khadeir, Ramsay, Corbacho, Javier Garcia, Repana, Dimitra, Steele, Jeremy P., Schmid, Peter, Szyszko, Teresa, Cook, Gary, Diaz, Monica, Feng, Xiaoxing, Johnston, Amanda, Thomson, Jim, Sheaff, Michael, Wu, Bor-Wen, Bomalaski, John, Pacey, Simon, Szlosarek, Peter W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6141244/
https://ncbi.nlm.nih.gov/pubmed/28388291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.71.3230
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados